Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1993 1
1995 1
1999 3
2000 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
Gehr TW, Sica DA, Grasela DM, Duchin KL. Gehr TW, et al. Eur J Clin Pharmacol. 1993;45(5):431-6. doi: 10.1007/BF00315514. Eur J Clin Pharmacol. 1993. PMID: 8112372 Clinical Trial.
Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng.ml-1, 5.2 h and 29.2%. Para-hydroxy fosinoprilat and fosinoprilat glucuronide comprised approximately …
Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailabi …
Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
Kostis JB, Garland WT, Delaney C, Norton J, Liao WC. Kostis JB, et al. Clin Pharmacol Ther. 1995 Dec;58(6):660-5. doi: 10.1016/0009-9236(95)90022-5. Clin Pharmacol Ther. 1995. PMID: 8529331 Clinical Trial.
Fosinoprilat, the active product of fosinopril, is eliminated by a hepatic pathway, in addition to the renal pathway shared by other angiotensin converting enzyme inhibitors. ...Thus these data indicate that patients with CHF can receive fosinopril without undue increases …
Fosinoprilat, the active product of fosinopril, is eliminated by a hepatic pathway, in addition to the renal pathway shared by other …
Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects.
Ding PY, Chu KM, Hu OY, Huang GM, Jeng JJ, Chang A, Delaney CL, MacAskill M, Yang BC, Jemal M, Smith R, Liao WC. Ding PY, et al. J Clin Pharmacol. 1999 Feb;39(2):155-60. doi: 10.1177/00912709922007705. J Clin Pharmacol. 1999. PMID: 11563407 Clinical Trial.
Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilatin a randomized sequence with sampling for fosinoprilat concentrations over 48 hours. Standard pharmacokinetics, including AUC, Cmax Tmax, T 1/2, Vss, bioavailability, total clearance, and renal and …
Each subject received 10 mg of oral fosinopril or 7.5 mg of IV fosinoprilatin a randomized sequence with sampling for fosinoprilat co …
Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
Greenbaum R, Zucchelli P, Caspi A, Nouriel H, Paz R, Sclarovsky S, O'Grady P, Yee KF, Liao WC, Mangold B. Greenbaum R, et al. Br J Clin Pharmacol. 2000 Jan;49(1):23-31. doi: 10.1046/j.1365-2125.2000.00103.x. Br J Clin Pharmacol. 2000. PMID: 10606834 Free PMC article. Clinical Trial.
AIMS: To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosinopril, enalapril and lisinopril. ...Similarly, the difference between the AI for fosinoprilat (1.21) and lisinopril (2.76) was statist …
AIMS: To compare the serum pharmacokinetics of fosinoprilat with enalaprilat and lisinopril after 1 and 10 days of dosing with fosino …
In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Azizi M, Massien C, Michaud A, Corvol P. Azizi M, et al. Hypertension. 2000 Jun;35(6):1226-31. doi: 10.1161/01.hyp.35.6.1226. Hypertension. 2000. PMID: 10856268 Clinical Trial.
In vitro, omapatrilat was 5 times more potent than fosinoprilat in inhibiting angiotensin I hydrolysis. Omapatrilat inhibited similarly both N- and C-domain hydrolysis, whereas fosinoprilat was slightly more specific for the N-domain. ...
In vitro, omapatrilat was 5 times more potent than fosinoprilat in inhibiting angiotensin I hydrolysis. Omapatrilat inhibited similar …
Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction.
Uderman HD, Much DR, Brennan J, Delaney CL, Morgenthien EA, Weaver J, Stouffer BC, Chang SY, VanHarken D, Liao W. Uderman HD, et al. Ann Pharmacother. 1999 May;33(5):525-30. doi: 10.1345/aph.18228. Ann Pharmacother. 1999. PMID: 10369612 Clinical Trial.
RESULTS: There was no evidence of any significant effect of HCTZ on the pharmacokinetics of fosinoprilat, based on maximum concentration value, AUC, or cumulative urinary recovery over 24 hours. Fosinoprilat had no clinically important effect on the pharmacokinetics …
RESULTS: There was no evidence of any significant effect of HCTZ on the pharmacokinetics of fosinoprilat, based on maximum concentrat …
Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA. Duchin KL, et al. J Clin Pharmacol. 1991 Jan;31(1):58-64. doi: 10.1002/j.1552-4604.1991.tb01887.x. J Clin Pharmacol. 1991. PMID: 1646240 Clinical Trial.
Serum aldosterone levels, ACE activity, and sitting blood pressure were determined, as were pharmacokinetic parameters of fosinoprilat, the active diacid of fosinopril. In a dose-tolerance study (study II), 80 and 160 mg of the drug were administered in doses of 40 mg bid …
Serum aldosterone levels, ACE activity, and sitting blood pressure were determined, as were pharmacokinetic parameters of fosinoprilat …
Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II.
Pool JL. Pool JL. Clin Ther. 1990 Nov-Dec;12(6):520-33. Clin Ther. 1990. PMID: 2149674 Clinical Trial.
No clinically significant abnormal laboratory test results were reported. Fosinoprilat, the active diacid of fosinopril, is eliminated by both the hepatobiliary and renal routes, which suggests that fosinopril may be particularly useful in the treatment of patients with im …
No clinically significant abnormal laboratory test results were reported. Fosinoprilat, the active diacid of fosinopril, is eliminate …
Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
O'Grady P, Yee KF, Lins R, Mangold B. O'Grady P, et al. Br J Clin Pharmacol. 1999 Sep;48(3):375-81. doi: 10.1046/j.1365-2125.1999.00013.x. Br J Clin Pharmacol. 1999. PMID: 10510149 Free PMC article. Clinical Trial.
AIMS: Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by other angiotensin converting enzyme inhibitors (ACEIs). ...CONCLUSIONS: In renally impaired subjects fosinopril and HCTZ can be coadminister …
AIMS: Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by …
Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.
Murdoch D, McTavish D. Murdoch D, et al. Drugs. 1992 Jan;43(1):123-40. doi: 10.2165/00003495-199243010-00009. Drugs. 1992. PMID: 1372856 Review.
Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin converting enzyme (ACE) inhibitor fosinoprilat. Unlike other ACE inhibitors, fosinoprilat has a compensatory dual route of elim …
Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin c …